DK3383385T3 - Melflufen-doseringsregimer for cancer - Google Patents

Melflufen-doseringsregimer for cancer Download PDF

Info

Publication number
DK3383385T3
DK3383385T3 DK16805792.5T DK16805792T DK3383385T3 DK 3383385 T3 DK3383385 T3 DK 3383385T3 DK 16805792 T DK16805792 T DK 16805792T DK 3383385 T3 DK3383385 T3 DK 3383385T3
Authority
DK
Denmark
Prior art keywords
cancer
dosage regimens
melflufen
melflufen dosage
regimens
Prior art date
Application number
DK16805792.5T
Other languages
English (en)
Other versions
DK3383385T4 (da
Inventor
Jakob Lindberg
Original Assignee
Oncopeptides Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55177548&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3383385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Oncopeptides Ab filed Critical Oncopeptides Ab
Publication of DK3383385T3 publication Critical patent/DK3383385T3/da
Application granted granted Critical
Publication of DK3383385T4 publication Critical patent/DK3383385T4/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/223Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of alpha-aminoacids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK16805792.5T 2015-12-01 2016-12-01 Melflufen-doseringsregimer for cancer DK3383385T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1521217.8A GB201521217D0 (en) 2015-12-01 2015-12-01 Dosage regimens
PCT/EP2016/079511 WO2017093443A1 (en) 2015-12-01 2016-12-01 Melflufen dosage regimens for cancer

Publications (2)

Publication Number Publication Date
DK3383385T3 true DK3383385T3 (da) 2020-10-12
DK3383385T4 DK3383385T4 (da) 2023-11-06

Family

ID=55177548

Family Applications (1)

Application Number Title Priority Date Filing Date
DK16805792.5T DK3383385T4 (da) 2015-12-01 2016-12-01 Melflufen-doseringsregimer for cancer

Country Status (27)

Country Link
US (3) US20180369141A1 (da)
EP (3) EP3903777A1 (da)
JP (2) JP6878431B2 (da)
KR (2) KR102279629B1 (da)
CN (1) CN108289876A (da)
AU (2) AU2016363591B2 (da)
BR (1) BR112018010012A8 (da)
CA (1) CA3003102C (da)
CY (1) CY1123469T1 (da)
DK (1) DK3383385T4 (da)
ES (1) ES2828033T5 (da)
FI (1) FI3383385T4 (da)
GB (1) GB201521217D0 (da)
HR (1) HRP20201632T4 (da)
HU (1) HUE051525T2 (da)
IL (2) IL301019B2 (da)
LT (1) LT3383385T (da)
MX (2) MX384724B (da)
PL (1) PL3383385T5 (da)
PT (1) PT3383385T (da)
RS (1) RS60986B2 (da)
RU (2) RU2020134307A (da)
SG (1) SG11201803551YA (da)
SI (1) SI3383385T2 (da)
SM (1) SMT202000567T1 (da)
WO (1) WO2017093443A1 (da)
ZA (2) ZA201802816B (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12152087B2 (en) * 2018-10-18 2024-11-26 Oncopeptides Innovation Ab Deuterated melflufen compounds
JP7712206B2 (ja) * 2019-01-28 2025-07-23 サノフィ-アベンティス・ユー・エス・エルエルシー 多発性骨髄腫の処置方法
WO2020201542A1 (en) * 2019-04-03 2020-10-08 Oncopeptides Ab Treatment of al amyloidosis with melflufen
GB201905477D0 (en) * 2019-04-17 2019-05-29 Oncopeptides Ab Novel formulations
WO2021053185A1 (en) * 2019-09-20 2021-03-25 Oncopeptides Ab Melflufen formulations and their use in the treatment or prophylaxis of osteosarcoma
SE544998C2 (en) * 2021-01-13 2023-02-21 Bkmdcl Ab Peptide conjugates of melphalan for the treatment of cancer
JP2024524552A (ja) * 2021-07-08 2024-07-05 オンコペプティデス エービー 多発性骨髄腫の治療に使用するためのメルフルフェン

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0002202D0 (sv) * 2000-06-13 2000-06-13 Karolinska Innovations Ab New peptides
DK2701720T3 (da) 2011-04-28 2017-10-09 Oncopeptides Ab Lyofiliseret præparat med cytotoksiske dipeptider
EP2909690B1 (en) 2012-10-22 2017-07-19 Parker Hannifin Manufacturing Sweden AB Joystick for utility vehicles
SMT202000058T1 (it) * 2012-10-26 2020-03-13 Oncopeptides Ab Preparazioni liofilizzate di melfalan flufenammide
NZ713868A (en) * 2013-04-08 2021-12-24 Berg Llc Treatment of cancer using coenzyme q10 combination therapies

Also Published As

Publication number Publication date
NZ742548A (en) 2023-10-27
ZA202102438B (en) 2025-08-27
IL301019A (en) 2023-05-01
MX2021008738A (es) 2021-08-24
KR102279629B1 (ko) 2021-07-20
FI3383385T4 (fi) 2023-11-01
CY1123469T1 (el) 2022-03-24
AU2016363591B2 (en) 2020-12-10
EP3383385B1 (en) 2020-07-29
ES2828033T3 (es) 2021-05-25
LT3383385T (lt) 2020-12-28
PT3383385T (pt) 2020-10-26
SMT202000567T1 (it) 2020-11-10
CA3003102C (en) 2022-09-13
CN108289876A (zh) 2018-07-17
MX2018006706A (es) 2018-08-01
US20220047507A1 (en) 2022-02-17
DK3383385T4 (da) 2023-11-06
ES2828033T5 (es) 2024-04-04
US20250144023A1 (en) 2025-05-08
AU2016363591A1 (en) 2018-06-28
EP3383385B2 (en) 2023-09-06
BR112018010012A2 (pt) 2018-11-21
RS60986B1 (sr) 2020-11-30
RU2734930C2 (ru) 2020-10-26
RS60986B2 (sr) 2023-12-29
EP3383385A1 (en) 2018-10-10
JP2019501881A (ja) 2019-01-24
CA3003102A1 (en) 2017-06-08
PL3383385T3 (pl) 2021-05-04
SG11201803551YA (en) 2018-05-30
EP3903777A1 (en) 2021-11-03
SI3383385T2 (sl) 2024-01-31
RU2018123718A (ru) 2020-01-09
BR112018010012A8 (pt) 2019-02-26
JP2021088560A (ja) 2021-06-10
AU2021200436A1 (en) 2021-02-25
WO2017093443A1 (en) 2017-06-08
IL301019B1 (en) 2025-08-01
SI3383385T1 (sl) 2020-11-30
IL301019B2 (en) 2025-12-01
JP6878431B2 (ja) 2021-05-26
KR20210092327A (ko) 2021-07-23
ZA201802816B (en) 2021-07-28
US20180369141A1 (en) 2018-12-27
HRP20201632T4 (hr) 2023-11-10
RU2020134307A (ru) 2020-11-27
EP3750534A1 (en) 2020-12-16
MX384724B (es) 2025-03-14
HUE051525T2 (hu) 2021-03-01
IL259101A (en) 2018-06-28
KR20180087254A (ko) 2018-08-01
HRP20201632T1 (hr) 2021-01-08
PL3383385T5 (pl) 2023-12-18
RU2018123718A3 (da) 2020-04-02
GB201521217D0 (en) 2016-01-13

Similar Documents

Publication Publication Date Title
IL255217A0 (en) Cancer neoepitopes
DK3265421T3 (da) Doseringssystem
HUE053903T2 (hu) Kombinációs terápia rák ellen
LT3119808T (lt) Antikūnų kompozicijos vėžio gydymui
HUE054012T2 (hu) Kombinációs terápia rák ellen
DK3310231T3 (da) Doseringsindretning
PL3197456T3 (pl) Leczenie nowotworów
DK4197530T3 (da) Ribociclib-tablet
EP3413927A4 (en) CANCER THERAPY
IL258525A (en) Dosing regimens
DK3383385T3 (da) Melflufen-doseringsregimer for cancer
DK3363428T3 (da) Perfusionsdoseringsform
HUE040167T2 (hu) Rákkezelés
HUE056897T2 (hu) Monomaleimid-funkcionalizált platinavegyületek rákterápiához
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
KR20180084810A (ko) 정제 세트
DK3215223T3 (da) Buprenorphindoseringsskemaer
DK3126791T3 (da) Doseringsanordning
EP3334447A4 (en) CCK2R-drug conjugates
DK3281641T3 (da) Adjuvans til cancervacciner
DK3277325T3 (da) Kombinationsimmunterapi for cancer
DK3288967T3 (da) Farmaceutisk forbindelse
DK3288966T3 (da) Farmaceutisk forbindelse
TH1501007353A (th) สารประกอบชนิดใหม่สำหรับการบำบัดโรคมะเร็ง